NHD Global
Peptides acting on the growth hormone / IGF-1 axis fall into two broad groups: GHRH analogues that act on the pituitary GHRH receptor, and ghrelin-mimetic secretagogues acting on GHS-R1a.
This section also covers IGF-1 variants and the modified-release analogues used where a longer half-life is required.
Continue from catalog navigation into editorial analysis, evidence records and quality-documentation guidance.
Showing 1–6 of 22 reviewed articles · Page 1 of 4
“PEG-MGF” is not a complete molecular identity. A defensible material record must define the peptide, PEG architecture, attachment chemistry, site distribution and…
Read source review →Direct evidence for a defined covalently PEGylated MGF product is sparse. Several frequently cited papers instead placed native MGF peptide inside PEGDMA…
Read source review →Hexarelin, also called Examorelin, is an amidated synthetic hexapeptide. The 2-methyl substitution on D-tryptophan distinguishes it from related GHRPs.
Read source review →Hexarelin has controlled human pharmacology data, but the central evidence is an acute 12-person GH dose-response experiment rather than a clinical-outcome trial.
Read source review →GHRP-6 is the amidated hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Its D residues, terminal amide, counterion and content basis are identity-critical.
Read source review →GHRP-6 can provoke growth-hormone release in controlled human experiments, but the response depends heavily on intact hypothalamic GHRH signaling and does not…
Read source review →If a target is not listed, submit the sequence, scale and specification for a custom-project feasibility review.
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
